Publikationen in Zusammenarbeit mit Forschern von University of Oslo (12)

2024

  1. Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis

    Haematologica, Vol. 109, Núm. 7, pp. 2239-2249

2023

  1. Cobimetinib Alone and Plus Venetoclax With/Without Atezolizumab in Patients With Relapsed/Refractory Multiple Myeloma

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 23, Núm. 1, pp. e59-e70

  2. Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)

    Leukemia, Vol. 37, Núm. 6, pp. 1175-1185

  3. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network

    The Lancet Oncology, Vol. 24, Núm. 6, pp. e255-e269

2022

  1. Corrigendum: “Corrigendum to ‘Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’”: (Annals of Oncology (2022) 33(1) (117), (S0923753421044999), (10.1016/j.annonc.2021.10.001))

    Annals of Oncology

2021

  1. COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network

    The Lancet Haematology, Vol. 8, Núm. 12, pp. e934-e946

  2. Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study

    The Lancet Oncology, Vol. 22, Núm. 1, pp. 142-154

  3. Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up

    HemaSphere, Vol. 5, Núm. 2

  4. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

    Annals of Oncology, Vol. 32, Núm. 3, pp. 309-322

2019

  1. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

    The Lancet, Vol. 394, Núm. 10214, pp. 2096-2107

  2. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

    The Lancet, Vol. 393, Núm. 10168, pp. 253-264

  3. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

    The Lancet Oncology, Vol. 20, Núm. 6, pp. 781-794